Beijing Tong Ren Tang Chinese Medicine Co (3613) AI Stock Analysis

• Market Cap: HK$7.32B
• Dividend Yield: 3.99%
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): 14.2
• Beta (1Y): 0.74
• Revenue Growth: 24.13%
• EPS Growth: 4.29%
• Country: HK
• Employees: 782
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.28
• Shares Outstanding: 837,100,000
• 10 Day Avg. Volume: 975,850
• 30 Day Avg. Volume: 1,095,238
• PEG Ratio: -1.91
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 4.56
• P/FCF Ratio: -28.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: HK$9.50 ▲(7.71% Upside)

The overall stock score of 66 reflects strong financial performance, particularly in terms of balance sheet strength and profitability, which is the most significant factor. However, technical analysis indicates bearish momentum, which weighs down the score. The valuation is fair, with a reasonable P/E ratio and attractive dividend yield, providing some support to the overall score.

Beijing Tong Ren Tang Chinese Medicine Co Business Overview & Revenue Model

Company Description

Beijing Tong Ren Tang Chinese Medicine Co (3613) is a renowned company specializing in the production and distribution of traditional Chinese medicine (TCM) products. With a rich heritage dating back to 1669, the company is a leader in the TCM industry, offering a wide range of herbal medicines, health supplements, and wellness products. It operates across various sectors, including retail, wholesale, and healthcare services, catering to a global market with a strong presence in Asia, Europe, and the Americas.

How the Company Makes Money

Beijing Tong Ren Tang Chinese Medicine Co generates revenue primarily through the sale of its traditional Chinese medicine products. The company's revenue model includes direct retail sales through its network of stores and e-commerce platforms, as well as wholesale distribution to pharmacies, healthcare providers, and international markets. Key revenue streams include proprietary herbal formulations, over-the-counter health supplements, and wellness products. Significant partnerships with healthcare institutions and collaborations with research organizations also contribute to its earnings by enhancing product development and expanding market reach. Additionally, the company's strategic focus on integrating TCM with modern healthcare practices helps in tapping into new customer segments and increasing its revenue base.

Beijing Tong Ren Tang Chinese Medicine Co Financial Statement Overview

Summary

Beijing Tong Ren Tang Chinese Medicine Co demonstrates strong financial health with consistent revenue growth and solid profitability metrics. The balance sheet is particularly robust, with low debt levels and high equity, providing a cushion against financial instability. However, the recent absence of cash flow data poses a potential risk, requiring attention to ensure ongoing liquidity and operational funding.

Income Statement

Beijing Tong Ren Tang Chinese Medicine Co has shown consistent revenue growth over recent years, with a slight dip in 2024. The gross profit and EBIT margins are strong, indicating efficient operations and cost management. However, the net profit margin decreased slightly, reflecting potential challenges in controlling non-operating expenses or taxes.

Balance Sheet

The company maintains a robust balance sheet with a high equity ratio, indicating financial stability and low leverage risk. The debt-to-equity ratio is very low, suggesting prudent financial management. High stockholders' equity relative to total assets reflects a strong capital position.

Cash Flow

The company's free cash flow has been positive but shows volatility, with no data available for 2024. The high operating cash flow relative to net income in prior years indicates strong cash generation from operations, but the lack of recent data prevents a comprehensive assessment of current cash flow health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.71B	1.61B	1.52B	1.73B	1.56B	1.32B
Gross Profit	1.08B	1.07B	1.05B	1.15B	1.12B	952.90M
EBITDA	598.78M	722.32M	779.54M	907.63M	852.81M	769.14M
Net Income	515.36M	500.28M	540.39M	645.88M	607.84M	542.46M
Balance Sheet
Total Assets	4.53B	4.56B	4.43B	4.23B	3.83B	3.42B
Cash, Cash Equivalents and Short-Term Investments	2.01B	1.82B	2.38B	2.24B	2.28B	1.85B
Total Debt	142.71M	123.42M	131.81M	103.08M	128.48M	106.01M
Total Liabilities	312.26M	313.09M	413.75M	486.49M	295.48M	287.46M
Stockholders Equity	4.03B	4.08B	3.87B	3.60B	3.42B	3.02B
Cash Flow
Free Cash Flow	518.75M	-260.42M	438.96M	508.94M	753.74M	103.17M
Operating Cash Flow	567.10M	-217.25M	460.83M	547.44M	777.17M	116.05M
Investing Cash Flow	-153.66M	1.35B	-1.08B	335.41M	-265.73M	506.73M
Financing Cash Flow	-335.60M	-355.30M	-372.18M	-535.42M	-278.65M	-264.30M

Beijing Tong Ren Tang Chinese Medicine Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3613, the sentiment is Positive. The current price of 8.82 is above the 20-day moving average (MA) of 8.77, below the 50-day MA of 8.92, and above the 200-day MA of 8.58, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 48.52 is Neutral, neither overbought nor oversold. The STOCH value of 78.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3613.

Beijing Tong Ren Tang Chinese Medicine Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6896	75 Outperform	HK$2.56B	8.82	21.47%	14.49%	-2.70%	2.19%
2877	73 Outperform	HK$6.66B	7.47	10.85%	5.75%	-20.64%	-25.39%
1666	68 Neutral	$5.97B	12.84	5.98%	4.21%	0.73%	-34.04%
3613	66 Neutral	HK$7.32B	14.20	13.22%	3.99%	24.13%	4.29%
0570	54 Neutral	$11.63B	-40.67	-1.26%	3.40%	-9.58%	-128.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2616	42 Neutral	HK$8.81B	-19.44	-95.84%	―	-55.64%	-158.67%

Beijing Tong Ren Tang Chinese Medicine Co Corporate Events

Beijing Tong Ren Tang Expands Market with Cambodian License

Beijing Tong Ren Tang Chinese Medicine Company Limited has received a traditional medicine registration license from Cambodia’s Ministry of Health, allowing its product, Tong Ren Tang Angong Niuhuang Wan, to be sold in Cambodia. This development is expected to enhance the company’s distribution channels and market expansion, although it will not immediately impact the company’s production and performance. Factors such as policy changes and market competition in Cambodia could influence future sales.

The most recent analyst rating on (HK:3613) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.

Beijing Tong Ren Tang Chinese Medicine Co Announces Board Composition

Beijing Tong Ren Tang Chinese Medicine Co has announced the composition of its Board of Directors, highlighting the roles and functions of each member. This announcement provides clarity on the company’s governance structure, which may impact its strategic direction and reassure stakeholders about its leadership stability.

The most recent analyst rating on (HK:3613) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.

Leadership Transition at Beijing Tong Ren Tang Chinese Medicine Co

Beijing Tong Ren Tang Chinese Medicine Co announced the retirement of Mr. Gu Hai Ou as the executive director, chairman of the board, and authorized representative, effective September 4, 2025, due to reaching retirement age. Mr. Yan Han has been appointed as the new chairman of the board, bringing extensive experience in international culture publicity and brand development, while Mr. Yue Zheng has been appointed as the new authorized representative. These leadership changes are expected to influence the company’s strategic direction and reinforce its position in the traditional Chinese medicine industry.

The most recent analyst rating on (HK:3613) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.

Beijing Tong Ren Tang Reports Strong Interim Growth

Beijing Tong Ren Tang Chinese Medicine Co, a prominent player in the traditional Chinese medicine sector, specializes in the manufacturing, retail, and wholesale of Chinese medicine and healthcare products. The company recently reported its interim results for the first half of 2025, showcasing resilience amidst global economic challenges. The company achieved a notable revenue increase of 14.6% year-on-year, reaching HK$761.7 million, while profit attributable to owners rose by 6.9% to HK$234.9 million. This growth was supported by strategic market expansions, including new retail outlets and enhanced product packaging. The company also actively engaged in brand promotion and anti-counterfeiting efforts to safeguard its reputation. Looking forward, Beijing Tong Ren Tang aims to deepen its R&D initiatives and expand its product portfolio, leveraging both online and offline channels to drive sustainable growth in the evolving pharmaceutical landscape.

Beijing Tong Ren Tang Announces 2025 Interim Results

Beijing Tong Ren Tang Chinese Medicine Company Limited announced its unaudited interim results for the first half of 2025. The report, which complies with the Stock Exchange of Hong Kong’s listing rules, will be available to shareholders and online by the end of September 2025. This announcement reflects the company’s ongoing commitment to transparency and regulatory compliance, potentially impacting its market position and stakeholder confidence.

The most recent analyst rating on (HK:3613) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.

Beijing Tong Ren Tang Chinese Medicine Co Schedules Board Meeting for Interim Results

Beijing Tong Ren Tang Chinese Medicine Co announced a board meeting scheduled for August 22, 2025, to approve the interim results for the first half of the year and consider dividend payments. This meeting is significant as it will provide insights into the company’s financial health and potential returns for shareholders, impacting its market positioning and stakeholder interests.